Drug Trial Radar · NCT06589817
A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute Schizophrenia
Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
376
Planned (sponsor's estimate)
Start
Oct 2024
Primary completion
Jun 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a non-Inferiority trial to evaluate efficacy and safety of hydrochloride carliprazine capsules and aripiprazole tablets in treating acute schizophrenia in Chinese adults. 376 patients will be randomizdely assigned in a 1:1 ratio to treatment group and control group. All enrolled subjects will be orally administered with hydrochloride carliprazine capsules or aripiprazole tablets for 6 consecutive weeks.
Conditions
- Acute Schizophrenia
Interventions
Hydrochloride Carliprazine capsulesDrug
Oral administration, once daily, with a total treatment duration of 6 weeks after successful screening.
Aripiprazole tabletsDrug
Oral administration, once daily, with a total treatment duration of 6 weeks after successful screening.
Primary outcomes
What the sponsor says the trial is designed to measure.
- PANSSTime frame: week 6
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.